Chemotherapy: $70,000 in US but 2,500.00 in India! Why the difference?

India’s Supreme Court has rejected a bid from Swiss pharmaceutical company Novartis AG to patent an updated version of its cancer drug Gleevec (known as Glivec in Europe).
Patents allow companies to block competitors from making and selling the same product. The ruling means that Novartis can’t stop drug makers in India from manufacturing generic versions of Gleevec, which cost much less than the original.

http://crooksandliars.com/karoli/oncologists-rise-against-big-pharma